Selected research
Industry Research
Lacosamide Drugs Industry Research Report 2026
Market perspective
The global Lacosamide Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Lacosamide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Lacosamide Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Lacosamide Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Lacosamide Drugs include Zhejiang Huahai Pharmaceutical, CSPC Ouyi Pharmaceutical, Shijiazhuang No.4 Pharmaceutical, Shandong Loncom Pharmaceutical, Jiangxi Qingfeng Pharmaceutical, Jiangsu Haian Pharmaceutical, Jianmin Group, Hefei Yifan Biopharmaceuticals and Buchang Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Lacosamide Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lacosamide Drugs Market by Company
Zhejiang Huahai Pharmaceutical
CSPC Ouyi Pharmaceutical
Shijiazhuang No.4 Pharmaceutical
Shandong Loncom Pharmaceutical
Jiangxi Qingfeng Pharmaceutical
Jiangsu Haian Pharmaceutical
Jianmin Group
Hefei Yifan Biopharmaceuticals
Buchang Pharmaceutical
Beijing Sihuan Pharmaceutical
UCB Pharma
Teva
Sun Pharma
Sandoz
Mylan
Glenmark Pharmaceuticals
Camber Pharma
Aucta Pharma
Apotex
Actavis
Lacosamide Drugs Segment by Type
Oral Solution
Tablets
Injection
Lacosamide Drugs Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Lacosamide Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lacosamide Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lacosamide Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lacosamide Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Lacosamide Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Lacosamide Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Lacosamide Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Solution
- Tablets
- Injection
Applications
- Hospital and Clinic
- Retail Pharmacies
- Other
Companies covered
- Zhejiang Huahai Pharmaceutical
- CSPC Ouyi Pharmaceutical
- Shijiazhuang No.4 Pharmaceutical
- Shandong Loncom Pharmaceutical
- Jiangxi Qingfeng Pharmaceutical
- Jiangsu Haian Pharmaceutical
- Jianmin Group
- Hefei Yifan Biopharmaceuticals
- Buchang Pharmaceutical
- Beijing Sihuan Pharmaceutical
- UCB Pharma
- Teva
- Sun Pharma
- Sandoz
- Mylan
- Glenmark Pharmaceuticals
- Camber Pharma
- Aucta Pharma
- Apotex
- Actavis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Lacosamide Drugs Market Size (2021-2032)
- 2.2.2 Global Lacosamide Drugs Sales (2021-2032)
- 2.2.3 Global Lacosamide Drugs Market Average Price (2021-2032)
- 2.3 Lacosamide Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral Solution
- 2.3.3 Tablets
- 2.3.4 Injection
- 2.4 Lacosamide Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital and Clinic
- 2.4.3 Retail Pharmacies
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Lacosamide Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Lacosamide Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Lacosamide Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Lacosamide Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Lacosamide Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Lacosamide Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Lacosamide Drugs, Product Type & Application
- 3.8 Global Manufacturers of Lacosamide Drugs, Established Date
- 3.9 Global Lacosamide Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Zhejiang Huahai Pharmaceutical
- 4.1.1 Zhejiang Huahai Pharmaceutical Company Information
- 4.1.2 Zhejiang Huahai Pharmaceutical Business Overview
- 4.1.3 Zhejiang Huahai Pharmaceutical Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Zhejiang Huahai Pharmaceutical Lacosamide Drugs Product Portfolio
- 4.1.5 Zhejiang Huahai Pharmaceutical Recent Developments
- 4.2 CSPC Ouyi Pharmaceutical
- 4.2.1 CSPC Ouyi Pharmaceutical Company Information
- 4.2.2 CSPC Ouyi Pharmaceutical Business Overview
- 4.2.3 CSPC Ouyi Pharmaceutical Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 CSPC Ouyi Pharmaceutical Lacosamide Drugs Product Portfolio
- 4.2.5 CSPC Ouyi Pharmaceutical Recent Developments
- 4.3 Shijiazhuang No.4 Pharmaceutical
- 4.3.1 Shijiazhuang No.4 Pharmaceutical Company Information
- 4.3.2 Shijiazhuang No.4 Pharmaceutical Business Overview
- 4.3.3 Shijiazhuang No.4 Pharmaceutical Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shijiazhuang No.4 Pharmaceutical Lacosamide Drugs Product Portfolio
- 4.3.5 Shijiazhuang No.4 Pharmaceutical Recent Developments
- 4.4 Shandong Loncom Pharmaceutical
- 4.4.1 Shandong Loncom Pharmaceutical Company Information
- 4.4.2 Shandong Loncom Pharmaceutical Business Overview
- 4.4.3 Shandong Loncom Pharmaceutical Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Shandong Loncom Pharmaceutical Lacosamide Drugs Product Portfolio
- 4.4.5 Shandong Loncom Pharmaceutical Recent Developments
- 4.5 Jiangxi Qingfeng Pharmaceutical
- 4.5.1 Jiangxi Qingfeng Pharmaceutical Company Information
- 4.5.2 Jiangxi Qingfeng Pharmaceutical Business Overview
- 4.5.3 Jiangxi Qingfeng Pharmaceutical Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Jiangxi Qingfeng Pharmaceutical Lacosamide Drugs Product Portfolio
- 4.5.5 Jiangxi Qingfeng Pharmaceutical Recent Developments
- 4.6 Jiangsu Haian Pharmaceutical
- 4.6.1 Jiangsu Haian Pharmaceutical Company Information
- 4.6.2 Jiangsu Haian Pharmaceutical Business Overview
- 4.6.3 Jiangsu Haian Pharmaceutical Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Jiangsu Haian Pharmaceutical Lacosamide Drugs Product Portfolio
- 4.6.5 Jiangsu Haian Pharmaceutical Recent Developments
- 4.7 Jianmin Group
- 4.7.1 Jianmin Group Company Information
- 4.7.2 Jianmin Group Business Overview
- 4.7.3 Jianmin Group Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Jianmin Group Lacosamide Drugs Product Portfolio
- 4.7.5 Jianmin Group Recent Developments
- 4.8 Hefei Yifan Biopharmaceuticals
- 4.8.1 Hefei Yifan Biopharmaceuticals Company Information
- 4.8.2 Hefei Yifan Biopharmaceuticals Business Overview
- 4.8.3 Hefei Yifan Biopharmaceuticals Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Hefei Yifan Biopharmaceuticals Lacosamide Drugs Product Portfolio
- 4.8.5 Hefei Yifan Biopharmaceuticals Recent Developments
- 4.9 Buchang Pharmaceutical
- 4.9.1 Buchang Pharmaceutical Company Information
- 4.9.2 Buchang Pharmaceutical Business Overview
- 4.9.3 Buchang Pharmaceutical Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Buchang Pharmaceutical Lacosamide Drugs Product Portfolio
- 4.9.5 Buchang Pharmaceutical Recent Developments
- 4.10 Beijing Sihuan Pharmaceutical
- 4.10.1 Beijing Sihuan Pharmaceutical Company Information
- 4.10.2 Beijing Sihuan Pharmaceutical Business Overview
- 4.10.3 Beijing Sihuan Pharmaceutical Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Beijing Sihuan Pharmaceutical Lacosamide Drugs Product Portfolio
- 4.10.5 Beijing Sihuan Pharmaceutical Recent Developments
- 4.11 UCB Pharma
- 4.11.1 UCB Pharma Company Information
- 4.11.2 UCB Pharma Business Overview
- 4.11.3 UCB Pharma Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 UCB Pharma Lacosamide Drugs Product Portfolio
- 4.11.5 UCB Pharma Recent Developments
- 4.12 Teva
- 4.12.1 Teva Company Information
- 4.12.2 Teva Business Overview
- 4.12.3 Teva Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Teva Lacosamide Drugs Product Portfolio
- 4.12.5 Teva Recent Developments
- 4.13 Sun Pharma
- 4.13.1 Sun Pharma Company Information
- 4.13.2 Sun Pharma Business Overview
- 4.13.3 Sun Pharma Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Sun Pharma Lacosamide Drugs Product Portfolio
- 4.13.5 Sun Pharma Recent Developments
- 4.14 Sandoz
- 4.14.1 Sandoz Company Information
- 4.14.2 Sandoz Business Overview
- 4.14.3 Sandoz Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Sandoz Lacosamide Drugs Product Portfolio
- 4.14.5 Sandoz Recent Developments
- 4.15 Mylan
- 4.15.1 Mylan Company Information
- 4.15.2 Mylan Business Overview
- 4.15.3 Mylan Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Mylan Lacosamide Drugs Product Portfolio
- 4.15.5 Mylan Recent Developments
- 4.16 Glenmark Pharmaceuticals
- 4.16.1 Glenmark Pharmaceuticals Company Information
- 4.16.2 Glenmark Pharmaceuticals Business Overview
- 4.16.3 Glenmark Pharmaceuticals Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Glenmark Pharmaceuticals Lacosamide Drugs Product Portfolio
- 4.16.5 Glenmark Pharmaceuticals Recent Developments
- 4.17 Camber Pharma
- 4.17.1 Camber Pharma Company Information
- 4.17.2 Camber Pharma Business Overview
- 4.17.3 Camber Pharma Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Camber Pharma Lacosamide Drugs Product Portfolio
- 4.17.5 Camber Pharma Recent Developments
- 4.18 Aucta Pharma
- 4.18.1 Aucta Pharma Company Information
- 4.18.2 Aucta Pharma Business Overview
- 4.18.3 Aucta Pharma Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Aucta Pharma Lacosamide Drugs Product Portfolio
- 4.18.5 Aucta Pharma Recent Developments
- 4.19 Apotex
- 4.19.1 Apotex Company Information
- 4.19.2 Apotex Business Overview
- 4.19.3 Apotex Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Apotex Lacosamide Drugs Product Portfolio
- 4.19.5 Apotex Recent Developments
- 4.20 Actavis
- 4.20.1 Actavis Company Information
- 4.20.2 Actavis Business Overview
- 4.20.3 Actavis Lacosamide Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Actavis Lacosamide Drugs Product Portfolio
- 4.20.5 Actavis Recent Developments
5 Global Lacosamide Drugs Market Scenario by Region
- 5.1 Global Lacosamide Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Lacosamide Drugs Sales by Region: 2021-2032
- 5.2.1 Global Lacosamide Drugs Sales by Region: 2021-2026
- 5.2.2 Global Lacosamide Drugs Sales by Region: 2027-2032
- 5.3 Global Lacosamide Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Lacosamide Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Lacosamide Drugs Revenue by Region: 2027-2032
- 5.4 North America Lacosamide Drugs Market Facts & Figures by Country
- 5.4.1 North America Lacosamide Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Lacosamide Drugs Sales by Country (2021-2032)
- 5.4.3 North America Lacosamide Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Lacosamide Drugs Market Facts & Figures by Country
- 5.5.1 Europe Lacosamide Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Lacosamide Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Lacosamide Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Lacosamide Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Lacosamide Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Lacosamide Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Lacosamide Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Lacosamide Drugs Market Facts & Figures by Country
- 5.7.1 South America Lacosamide Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Lacosamide Drugs Sales by Country (2021-2032)
- 5.7.3 South America Lacosamide Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Lacosamide Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Lacosamide Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Lacosamide Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Lacosamide Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Lacosamide Drugs Sales by Type (2021-2032)
- 6.1.1 Global Lacosamide Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Lacosamide Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Lacosamide Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Lacosamide Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Lacosamide Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Lacosamide Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Lacosamide Drugs Sales by Application (2021-2032)
- 7.1.1 Global Lacosamide Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Lacosamide Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Lacosamide Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Lacosamide Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Lacosamide Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Lacosamide Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Lacosamide Drugs Value Chain Analysis
- 8.1.1 Lacosamide Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Lacosamide Drugs Production Mode & Process
- 8.2 Lacosamide Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Lacosamide Drugs Distributors
- 8.2.3 Lacosamide Drugs Customers
9 Global Lacosamide Drugs Analyzing Market Dynamics
- 9.1 Lacosamide Drugs Industry Trends
- 9.2 Lacosamide Drugs Industry Drivers
- 9.3 Lacosamide Drugs Industry Opportunities and Challenges
- 9.4 Lacosamide Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst